A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors - No Study Results Posted

A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors (SF112600106)

This study is currently recruiting participants.

Study NCT00907205 Information provided by Semafore Pharmaceuticals

First Received: May 20, 2009 Last Updated: May 21, 2009 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	December 2009
Estimated Primary Completion Date:	December 2009 (Final data collection date for primary outcome measure)